KIT exon 11 and exon 9 mutations represent the two most common types of mutations (wild-type GIST is technically not a type of mutation but a lack of mutations) found in GIST patients. About 60 to 65 percent of GIST patients have a KIT exon 11 mutation and about 10 to15 percent have a KIT exon 9 mutation.
In a parallel phase II adjuvant trial of imatinib alone in high-risk GIST patients (tumors greater than 10 cm) researchers found a similar response pattern over the one year of the trial treatment period. They also found that when adjuvant treatment was stopped there was a significant increase in the rate of recurrence beginning six months after treatment was discontinued.
Treatment strategies & mutational testing were among key topics at CTOS 2008. There were also other presentations and posters regarding GIST were presented at the Connective Tissue Oncology Society (CTOS) meeting on November 13 to [...]
If you didn't find what you were looking for, try a new search!
